Format

Send to

Choose Destination
J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S11-7.

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

Author information

1
Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. campese@usc.edu

Abstract

Statins reduce serum cholesterol and cardiovascular morbidity and mortality. The mechanisms for these beneficial effects are reviewed. Altered inflammatory responses and improved endothelial function mediated by statins are thought to be partly responsible for the reduction of morbidity and mortality as a result of cardiovascular events. In analogy, whether statins confer similar benefits on the kidney has not been established. This review critically considers the available data whereby dyslipidemia mediates renal dysfunction by modulating the inflammatory response to diverse cytokines. Also reviewed is the emerging database indicating that statins may modulate renal function by altering the response of the kidney to dyslipidemia.

PMID:
15938026
DOI:
10.1681/asn.2004110958
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center